Document Detail

Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Finnish Leukaemia Group.
MedLine Citation:
PMID:  8616075     Owner:  NLM     Status:  MEDLINE    
DAta from an 8-year follow-up of 432 myeloma patients were analysed for incidence, duration and prognostic value of plateau phase and factors favouring its achievement. The first-line chemotherapy was melphalan and prednisolone in 121 cases, combination chemotherapy in 311 cases. The survival times were similar despite different response rates. Any response resulted in survival significantly (P<0.001) better than in patients with progressive disease, but the level of response had no influence in this respect. A plateau of at least 3 months was achieved in 81%, at least 6 months in 74%, at least 12 months in 59% and at least 24 months in 33%. Groups with significantly different (P<0.001) survivals were identified: a plateau of <3 months, 3-11 months, 12-23 months, and 24 months or longer, with median survivals of 10, 27, 46 and 81 months, respectively. In the multivariate analysis of pretreatment variables, only haemoglobin (Hb) (P<0.001) and creatinine at 2 months (P<0.01) were significant for a plateau >12 months. After inclusion of chemotherapy data, Hb and time taken to reach the best response were still significant (P=0.002). The predictive power of high Hb and slow response for achieving a plateau of 6 or 12 months was 79%. Accordingly, the criteria for response of treatment for multiple myeloma should include a stable period of at least 3 months; the criteria for a plateau a stable period of at least 12 months in order to have real prognostic significance.
T M Oivanen
Related Documents :
3304465 - High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant mu...
18056185 - Benefit of complete response in multiple myeloma limited to high-risk subgroup identifi...
17875535 - Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive ...
15327525 - Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and che...
7641745 - Ondansetron in chemotherapy-induced emesis. our experience.
1579715 - Survival in patients with superior pulmonary sulcus tumors.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of haematology     Volume:  92     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  1996 Mar 
Date Detail:
Created Date:  1996-06-12     Completed Date:  1996-06-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  834-9     Citation Subset:  IM    
Finnish Leukaemia Group, Department of Oncology, Tampere University Hospital, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Follow-Up Studies
Multiple Myeloma / drug therapy*
Prospective Studies
Survival Analysis
Survival Rate
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A case of refractory anaemia with p53 point mutation at codon 249 (AGG to ATG).
Next Document:  Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein...